Variants of HCMV UL18 Sequenced Directly from Clinical Specimens Associate with Antibody and T-Cell Responses to HCMV

Figures

• 

  Figure 1. (A) All nucleotide variations identified in HCMV UL18 sequenced in 60 samples. Variations are displayed in reference to HCMV Toledo. Blue bars represent A, green bars represent G, black bars represent T, and red bars represent C. (B) All nonsynonymous mutations identified in HCMV UL18 sequenced in 60 samples. Variations are displayed in reference to HCMV Toledo. Amino acids are represented by their one-letter codes. Each variation presented was found in at least 3 samples. The height of the bars represents the number of samples carrying the variation.

• 

  Figure 2. PWH with S318N carried lower levels of HCMV-reactive antibodies and/or inflammatory biomarkers over 6 months on ART. (A) comparison of HCMV lysate-reactive antibodies in PWH with S at position 318 and those with either S/N or N over time on ART. (B) plasma soluble IFNαR levels in PWH with HCMV with S at position 318 versus those with S/N or N; (C) plasma CRP levels in PWH with HCMV with S at position 318 versus those with S/N or N. V0 = before ART; V1, V3, V6, V12 = 1, 3, 6 or 12 months on ART resp. Red lines mark median values.

• 

  Figure 3. PWH carrying A107T had higher levels of HCMV reactive antibody levels and inflammatory biomarkers over time. (A) HCMV lysate-reactive antibodies at V0 (0 months on ART) with A, A/T or T at position 107; (B) HCMV lysate-reactive antibodies at V1 (1 month on ART) with A, A/T or T at position 107; (C) HCMV IE-1-reactive antibodies at V3 (3 months on ART) with A, A/T or T at position 107; (D) plasma soluble IFNαR levels at V0 with A, A/T or T at position 107; (E) plasma CRP levels at V1 with A, A/T or T at position 107. Red lines mark median values.